MCG In Long QT Syndrome

N/ANot Yet RecruitingNCT07270211

Mayo Clinic100 enrolled

Overview

The primary objective of this observational study is to evaluate whether magnetocardiography (MCG) findings more accurately predict clinical outcomes in patients with acquired Long QT syndrome compared to ECG. The secondary objective is to assess differences in QT interval length between MCG and ECG. The primary safety objective is to characterize the safety profile of the CardiAQ MCG device.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Atrial Fibrillation

Interventions

MagnetocardiographyDIAGNOSTIC_TEST

MCG is a non-invasive, radiation-free imaging technique that detects the magnetic field generated by the electrical activity of the heart.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria 1. Age ≥ 18 years on the date of consent 2. Ability for participant to comply with study requirements 3. Written informed consent 4. Confirmed diagnosis of atrial fibrillation and receiving dofetilide for rhythm control in the inpatient setting. Exclusion Criteria 1. Pregnant or breastfeeding 2. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillators). 3. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan 4. Inability to lie down in a supine/inclined position and stay still on the examination bed 5. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Number of successful dofetilide loading using Magnetocardiography

Dofetilide loading is considered successful if the following conditions are met: 1. No excessive QTc prolongation QTc remains \<500 ms, and no \>15% increase from baseline. 2. No sustained VT or recurrent/symptomatic non-sustained VT (NSVT) suggestive of proarrhythmia. 3. No symptomatic bradycardia or hemodynamic instability 4. Stable renal function 5. No deterioration necessitating dose reduction or discontinuation. 6. Discharge on a stable dose

Time frame: Baseline

Number of successful dofetilide loading using Electrocardiogram

Time frame: Baseline

Secondary Outcomes

Magnetocardiography - QT interval length

QT interval length is a measurement from the start of the Q wave to the end of the T wave. This will be measured in seconds.

Time frame: Baseline

Electrocardiogram - QT interval length

QT interval length is a measurement from the start of the Q wave to the end of the T wave. This will be measured in seconds.

Time frame: Baseline

Central Contacts

Patsy Caceres Figueroa

CONTACT

507-266-3054 caceresfigueroa.patsy@mayo.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.